Novalix
Records under this name other than the patents Novalix holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
Showing 1 to 6 of 6 · Back to Novalix
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,309,241 | Naphthyridine Derivative Compounds Formerly held In force · High confidence | In force | High confidence | |
| US 9,527,844 | Naphthyridine Derivative Compounds Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 9,757,364 | Naphthyridine derivative compounds Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 10,280,170 | SUBSTITUTED 4,5,6,7-Tetrahydro-PYRAZOLO[1,5-a]PYRAZINE DERIVATIVES AND 5,6,7,8-Tetrahydro-4H-PYRAZOLO[1,5-a][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS Formerly held In force · High confidence | In force | High confidence | |
| US 10,526,316 | Quinoxaline and Pyridopyrazine Derivatives as PI3KB Inhibitors Formerly held In force · High confidence | In force | High confidence | |
| US 11,130,751 | Quinoxaline and Pyridopyrazine Derivatives as PI3K-BETA Inhibitors Lapsed on the fee record Ended Sep 28, 2025 · High confidence | Lapsed on the fee record | Ended Sep 28, 2025 | High confidence |